2025
CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE
Meng X, Lotan Y, Kella N, Koch M, Pavlovich C, George A, Michel K, Sprenkle P, Sonn G, Mynderse L, Anttinen M, Chin J, Inman B, Mehan R, Banapour P, Sharif-Afshar A, Woodrum D, Ghanouni P, Arora S, Macura K, Princenthal R, Cohen M, Staruch R, Clarke G, Costa D, Klotz L. CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE. Urologic Oncology Seminars And Original Investigations 2025, 43: 79. DOI: 10.1016/j.urolonc.2024.12.200.Peer-Reviewed Original ResearchRadical prostatectomyRandomized controlled trialsProstate cancerAblation therapyAlternative to radiation therapyLocalized prostate cancerPCa-specific deathPad-free continencePrimary safety endpointPoor patient acceptanceStandard of careOrgan-confinedProstatectomy groupSignificant functional impairmentMetastatic diseaseRadiation therapyOpen-labelEfficacy endpointSecondary endpointsSafety endpointsSurgical approachPivotal studiesEfficacy dataNon-inferioritySub-sitesSurgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2024
Proceedings from an international consensus meeting on ablation in urogenital diseases
Iezzi R, Contegiacomo A, De Filippis A, Gunn A, Atwell T, Mcclure T, Jing Z, Posa A, Scrofani A, Maresca A, Madoff D, Goldberg S, Kelekis A, Filippiadis D, Sala E, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Into Imaging 2024, 15: 267. PMID: 39514046, PMCID: PMC11549275, DOI: 10.1186/s13244-024-01841-2.Peer-Reviewed Original ResearchInternational Consensus MeetingAblation techniqueIntermediate-risk prostate cancerImage-guided ablation techniquesPreoperative surgical riskManagement of oncological diseasesRenal cell carcinomaConsensus meetingTraditional surgical treatmentGenitourinary tract diseaseFibroid SymptomCell carcinomaProstate cancerSurgical riskAblation therapyImprove patient outcomesTumor managementSurgical treatmentMechanism of actionEffective alternativeTherapeutic alternativeSite of applicationEffective treatmentUrogenital diseasesOncological diseasesPartial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis
Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. Life 2024, 14: 661. PMID: 38929645, PMCID: PMC11204969, DOI: 10.3390/life14060661.Peer-Reviewed Original ResearchOverall survivalHepatocellular carcinomaPartial hepatectomyTumor sizeAssociated with inferior overall survivalEarly-stage hepatocellular carcinomaEarly-stage HCC patientsInferior overall survivalHepatocellular carcinoma patientsAblation armCarcinoma patientsAblation therapyNo significant differenceTreatment regimensHCC patientsEmulated target trialSurgical proceduresEffect of ablationHepatectomyPatientsCompare treatment effectsClinical treatmentSignificant differencePropensity scoreLogistic regression
2022
Effect of weight loss on recurrence of atrial fibrillation after ablative therapy: a systematic review and meta-analysis
Park D, An S, Murthi M, Kattoor A, Kaur A, Ravi V, Huang H, Vij A. Effect of weight loss on recurrence of atrial fibrillation after ablative therapy: a systematic review and meta-analysis. Journal Of Interventional Cardiac Electrophysiology 2022, 64: 763-771. PMID: 35258752, DOI: 10.1007/s10840-022-01168-2.Peer-Reviewed Original ResearchConceptsRecurrence of AFStudy of patientsHistory of AFAblation therapyAtrial fibrillationWeight lossRate of recurrence of AFSubgroup analysisRecurrence of atrial fibrillationRisk ratioEffects of weight lossSubgroup analysis of studiesLong-term recurrenceLost weightWeight loss groupMethodsAn extensive literature searchSystematic reviewStudies of weight lossConclusionWeight lossLow recurrenceMedical therapyLoss groupResultsEight studiesRecurrenceTherapy
2019
Risk factors of malignant fluorodeoxyglucose-avid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy
Cho S, Kwon S, Kim J, Cho D, Na M, Kang S, Yoo S, Song H. Risk factors of malignant fluorodeoxyglucose-avid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy. Medicine 2019, 98: e14858. PMID: 31008921, PMCID: PMC6494284, DOI: 10.1097/md.0000000000014858.Peer-Reviewed Original ResearchConceptsFDG-avid lymph nodesPapillary thyroid cancerRecurrent papillary thyroid cancerRadioiodine ablation therapyLymph nodesRisk factorsPositron emission tomographyAblation therapyThyroid cancerLateral neck lymph node metastasisAdvanced papillary thyroid cancerNeck lymph node metastasisFDG positron emission tomographyRetrospective imaging reviewEmission tomographyDissected lymph nodesMetastatic lymph nodesPreoperative risk factorsPostoperative risk factorsLymph node metastasisEvaluation of patientsAssessment of risk factorsN1b stageStimulated thyroglobulinExtrathyroidal extension
2017
Laser Thermal Ablation for Metastases Failing Radiosurgery: A Multicentered Retrospective Study
Chaunzwa TL, Deng D, Leuthardt EC, Tatter SB, Mohammadi AM, Barnett GH, Chiang VL. Laser Thermal Ablation for Metastases Failing Radiosurgery: A Multicentered Retrospective Study. Neurosurgery 2017, 82: 56-63. PMID: 28419284, DOI: 10.1093/neuros/nyx142.Peer-Reviewed Original ResearchConceptsRadiosurgical failureRadiation necrosisTumor regrowthAblation therapyFluid-attenuated inversion recovery signalTreatment factorsMulticentered retrospective studyKarnofsky performance statusMetastatic brain lesionsThermal ablation therapyLow complication rateTraditional treatment optionsTreatment of metastasesInversion recovery signalLaser thermal ablationBrain metastasesPreoperative symptomsComplication ratePerformance statusSymptomatic improvementSymptomatic reliefPerilesional edemaRetrospective studySurgical dataTreatment options
2016
Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go
Savic LJ, Chapiro J, Hamm B, Gebauer B, Collettini F. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. RöFo 2016, 188: 735-745. PMID: 27074423, DOI: 10.1055/s-0042-104203.Peer-Reviewed Original ResearchConceptsClinical evidenceIrreversible electroporationInterventional oncologyPancreatic irreversible electroporationSite-specific complicationsAvailable clinical evidenceUse of IRELimited clinical evidenceFavorable safety profileTolerable morbidityOncologic efficacyPreclinical findingsBile ductSafety profileNeurovascular bundleInvasive treatmentLung parenchymaAblation therapySolid tumorsClinical settingTumor ablation therapyHeat sink effectNon-thermal fashionLiverTumor ablation
2014
Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma
Park H, Jeong G, Kwon S, Min J, Bom H, Park K, Cho S, Kang S, Kim J, Song H, Chong A, Yoo S. Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma. Nuclear Medicine And Molecular Imaging 2014, 48: 255-261. PMID: 26396629, PMCID: PMC4571662, DOI: 10.1007/s13139-014-0282-4.Peer-Reviewed Original ResearchPapillary thyroid carcinomaPreablative Tg levelI-131 ablation therapyPredictors of therapeutic failurePreablation TgTherapeutic failureTG levelsThyroid carcinomaAblation therapyDoses of radioactive iodine therapyI-123 whole-body scanChance of therapeutic failureStimulated serum thyroglobulin levelTherapeutic failure rateSerum thyroglobulin levelsRadioactive iodine therapyAnti-Tg antibodiesWhole-body scanSerum thyroglobulinStimulated TgThyroglobulin levelsIodine therapyT stageAnti-TgTumor size
2012
Short-Term Outcomes of Ablation Therapy for Hepatic Tumors: Evidence from the 2006–2009 Nationwide Inpatient Sample
Fox JP, Gustafson J, Desai MM, Hellan M, Thambi-Pillai T, Ouellette J. Short-Term Outcomes of Ablation Therapy for Hepatic Tumors: Evidence from the 2006–2009 Nationwide Inpatient Sample. Annals Of Surgical Oncology 2012, 19: 3677-3686. PMID: 22588470, DOI: 10.1245/s10434-012-2397-0.Peer-Reviewed Original ResearchConceptsProcedure-specific complicationsNationwide Inpatient SampleMetastatic liver tumorsOpen surgical approachHepatic tumorsPostoperative complicationsSurgical approachInpatient SampleLiver tumorsMultivariable logistic regression analysisTreatment-related morbidityCases/yearLogistic regression analysisResultsMost patientsTransfusion requirementsHospital morbidityAdverse eventsIntraoperative bleedingBackgroundRadiofrequency ablationHeart failureHepatic failurePatient factorsTerm outcomesLaparoscopic proceduresAblation therapy
2008
Evaluating the left atrium by magnetic resonance imaging
Hauser TH, Peters DC, Wylie JV, Manning WJ. Evaluating the left atrium by magnetic resonance imaging. EP Europace 2008, 10: iii22-iii27. PMID: 18955395, PMCID: PMC2573030, DOI: 10.1093/europace/eun223.Peer-Reviewed Original ResearchConceptsLeft atriumPulmonary veinsRecurrent atrial fibrillationAtrial fibrillation ablationMagnetic resonance imagingFibrillation ablationAtrial fibrillationVariant anatomyAblation therapyMagnetic resonance imaging methodResonance imagingAtriumVeinAnatomyCatheterFibrillationImaging methodTherapyPrevention
2003
Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer
Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer. American Journal Of Clinical Oncology 2003, 26: 312-316. PMID: 12796607, DOI: 10.1097/01.coc.0000020921.08768.1f.Peer-Reviewed Original ResearchConceptsProstate-specific antigenDigital rectal examinationHigh-risk localized prostate cancerAndrogen ablation therapyLocalized prostate cancerProstate cancerMagnetic resonance imagingLiposomal doxorubicinAblation therapyElevated serum prostate-specific antigenTreated with androgen ablative therapyCycles of liposomal doxorubicinHigh-risk prostate cancerMedian prostate-specific antigenSerum prostate-specific antigenEndorectal magnetic resonance imagingSeminal vesicle involvementT4 prostate cancerRisk of recurrenceTime of diagnosisClinical T3Prostate irradiationT2b diseaseExtracapsular diseasePlus radiotherapyNeoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity.
Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity. American Journal Of Clinical Oncology 2003, 26: 312. DOI: 10.1097/00000421-200306000-00021.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerProstate-specific antigenLocalized prostate cancerDigital rectal examinationAndrogen ablation therapyMagnetic resonance imagingProstate cancerTime of diagnosisAblation therapyT3 diseaseLiposomal doxorubicinDoxorubicin formulationsPrimary treatmentElevated serum prostate-specific antigenTreated with androgen ablative therapyClinical stage T3 diseaseCycles of liposomal doxorubicinInhibiting growth of xenograftsMedian prostate-specific antigenNeoadjuvant hormonal ablation therapyHigh-risk prostate cancerLocally advanced prostate cancerSerum prostate-specific antigenHormone-refractory prostate cancerEndorectal magnetic resonance imaging
2002
Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer
Petrylak D. Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer. European Urology Open Science 2002, 1: 15-23. DOI: 10.1016/s1569-9056(02)00005-2.Peer-Reviewed Original ResearchHormone-refractory prostate cancerBone painProstate cancerSerum prostate-specific antigen levelProstate-specific antigen levelPhase II trialPhase III trialsSoft tissue metastasesAndrogen ablation therapyEffective palliative therapyAdvanced prostate cancerCombination of mitoxantroneMetastatic prostate cancerTreatment of menHormonal therapyII trialIII trialsOverall survivalPalliative therapyPSA levelsTissue metastasesAntigen levelsTreatment optionsClinical trialsAblation therapy
2001
The development of androgen-independent prostate cancer
Feldman B, Feldman D. The development of androgen-independent prostate cancer. Nature Reviews Cancer 2001, 1: 34-45. PMID: 11900250, DOI: 10.1038/35094009.Peer-Reviewed Original ResearchConceptsDevelopment of androgen-independent prostate cancerAndrogen-independent prostate cancerProstate cancerEarly-stage prostate cancerAndrogen ablation therapyAnti-androgen therapyAndrogen independenceNormal prostateAblation therapyEffective therapyAnti-androgenAndrogenCancerTherapyProstateSurgerySurvivalActivity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
Oh W, George D, Hackmann K, Manola J, Kantoff P. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57: 122-126. PMID: 11164156, DOI: 10.1016/s0090-4295(00)00986-9.Peer-Reviewed Original ResearchConceptsAndrogen-independent prostate cancerProstate-specific antigenAndrogen ablation therapyProstate cancerPC-SPESTreatment of patientsAblation therapyPSA responseTreated with PC-SPESHistory of coronary artery diseasePotential predictors of responsePost-therapy declineProgressive prostate cancerMedian follow-upProstate cancer progressionPredictors of responseSecondary hormonal treatmentResponse to treatmentCoronary artery diseaseNipple tendernessPSA progressionPatient diedMedian durationMedian ageWell-tolerated
1999
Treatment of locally advanced prostate cancer: is chemotherapy the next step?
Oh W, Kantoff P. Treatment of locally advanced prostate cancer: is chemotherapy the next step? Journal Of Clinical Oncology 1999, 17: 3664-75. PMID: 10550165, DOI: 10.1200/jco.1999.17.11.3664.Peer-Reviewed Original ResearchConceptsLocally advanced prostate cancerManagement of locally advanced prostate cancerAdvanced prostate cancerExternal-beam radiotherapyHormone ablation therapyProstate cancerRadical prostatectomyHormone ablationAblation therapyPatients treated with hormonal therapyComponent of multimodality treatmentHormone-refractory prostate cancerTreatment approach to patientsNatural historyStandard treatment optionSingle modality treatmentApproach to patientsAssociated with higher ratesStandard of careProgression-freeRadiation therapyModality treatmentOverall survivalSystemic therapyHormone therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply